<area date-time="d4HCV"></area> Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2016 Dec;23(Suppl 5):772-783.
doi: 10.1245/s10434-016-5547-y. Epub 2016 Sep 8.

"VSports app下载" Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Rebecca M Dodson  1 , Richard P McQuellon  2 , Harveshp D Mogal  1 , Katharine E Duckworth  2 , Gregory B Russell  3 , Konstantinos I Votanopoulos  1 , Perry Shen  1 , Edward A Levine  4   5
Affiliations

Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Rebecca M Dodson et al. Ann Surg Oncol. 2016 Dec.

Abstract

Background: Cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases can alleviate symptoms and prolong survival at the expense of morbidity and quality of life (QoL). This study aimed to monitor QoL and outcomes before and after HIPEC. VSports手机版.

Methods: A prospective QoL trial of patients who underwent HIPEC for peritoneal metastases from 2000 to 2015 was conducted. The patients completed the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), the Functional Assessment of Cancer Therapy + Colon Subscale (FACT-C), the Brief Pain Inventory, the Center for Epidemiologic Studies Depression scale, and the Eastern Cooperative Oncology Group (ECOG) performance status at baseline, then 3, 6, 12, and 24 months after HIPEC V体育安卓版. The trial outcome index (TOI) was analyzed. Proportional hazards modeled the effect of baseline QoL on survival. .

Results: The 598 patients (53. 8 % female) in the study had a mean age of 53. 3 years. The overall 1-year survival rate was 76. 8 %, and the median survival period was 2. 9 years. The findings showed a minor morbidity rate of 29. 3 %, a major morbidity rate of 21. 7 %, and a 30-day mortality rate of 3. 5 %. The BPI (p < 0. 0001) and worst pain (p = 0. 004) increased at 3 months but returned to baseline at 6 months. After CS + HIPEC, FACT-C emotional well-being, SF-36 mental component score, and emotional health improved (all p < 0. 001). Higher baseline FACT-General (hazard ratio [HR], 0. 92; 95 % confidence interval [CI], 0. 09-0. 96), FACT-C (HR, 0. 73; 95 % CI 0. 65-0. 83), physical well-being (HR, 0. 71; 95 % CI 0. 64-0. 78), TOI (HR, 0. 87; 95 % CI 0. 84-0. 91), and SF-36 vitality (HR, 0. 88; 95 % CI 0. 83-0. 92) were associated with improved survival (all p < 0 V体育ios版. 001). Higher baseline BPI (HR, 1. 1; 95 % CI 1. 05-1. 14; p < 0. 0001), worst pain (HR, 1. 06; 95 % CI 1. 01-1. 10; p = 0. 01), and ECOG (HR, 1. 74; 95 % CI 1. 50-2. 01; p < 0. 0001) were associated with worse survival. .

Conclusions: Although HIPEC is associated with morbidity and detriments to QoL, recovery with good overall QoL typically occurs at or before 6 months VSports最新版本. Baseline QoL is associated with morbidity, mortality, and survival after HIPEC. .

PubMed Disclaimer

Conflict of interest statement

Disclosure: There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Quality of life parameters by time of measurement (a, b), depression score (c) and pain assessment (d)
Fig. 2
Fig. 2. Overall survival for entire series (a), stratified by primary site (b), PCI score (c) and R score (d)
See this image and copyright information in PMC

References (VSports手机版)

    1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43. doi: 10.1056/NEJMoa052985. - DOI - PubMed
    1. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43. doi: 10.1200/JCO.2003.04.187. - VSports最新版本 - DOI - PubMed
    1. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20–6. doi: 10.1001/archsurg.139.1.20. - DOI - PubMed
    1. Stewart JH, IV, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34. doi: 10.1007/s10434-006-9708-2. - DOI - PubMed
    1. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7. doi: 10.1200/JCO.2003.04.150. - DOI - PubMed

Publication types

MeSH terms

Substances